---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126346"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:57:26.153551+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025

## Summary
- Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.
- Cash & equivalents $551M; expected to fund operations at least into H1 2027.
- Positive 4D-150 interim data: 83% injection reduction in severe population; 70-87% 52-week injection-free rate.
- 4FRONT-1 Phase 3 trial for 4D-150 in wet AMD initiation expected Q1 2025.
- New senior hires: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophthalmology).

## SEC filing metadata
- accession: 0000950170-24-126346
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/0000950170-24-126346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126346
- JSON: https://secwatch.observer/filing/0000950170-24-126346.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.